Using a genetic strategy, depletion of GRP94 from specific cells reveals that GRP94 promotes tumorigenesis in multiple myeloma (10), liver cancer (20–22), colon cancer (23, 24), and endometrial carcinoma (25). Here, HSP90B1 is linked to plasma cell myeloma.